Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Immunomodulatory Effects of Everolimus in a Long Responsive Patient With Metastatic Renal Cell Carcinoma

Thiery-Vuillemin, Antoine*,†,‡; Laheurte, Caroline§,∥; Mansi, Laura*; Royer, Bernard†,¶; Pivot, Xavier*,†,‡; Borg, Christophe*,†,‡; Adotevi, Olivier*,†,‡

doi: 10.1097/CJI.0000000000000006
Clinical Studies
Buy

Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. Besides, mammalian target of rapamycin inhibition has the ability to modulate T-lymphocyte homeostasis. Here, we report the case of a metastatic renal cell carcinoma patient treated with everolimus who presented unexpected prolonged tumor response. The monitoring of immune responses showed strong antitumor T-cell activation at the time of disease control, whereas a profound immunosuppression occurred when tumor progressed. Thus, a change of immune functions is associated with everolimus treatment. Our observation suggests that everolimus could shape immune responses, which in turn could contribute to its efficacy.

*Oncologie, Besançon Cedex

§CIC-BT506, CHRU

INSERM, UMR1098

UMR1098, Université de Franche-Comté

EFS Bourgogne Franche-Comté

Laboratoire de Pharmacologie Clinique et Toxicologie, Besançon, France

Reprints: Antoine Thiery-Vuillemin, MD, Medical Oncology, University Hospital of Besançon, Boulevard Flemming, F-25030 Besançon cedex, France (e-mail: a.thieryvuillemin@mac.com).

Received July 2, 2013

Accepted October 13, 2013

© 2014 by Lippincott Williams & Wilkins